Skip to main content

Our vision

Big Data is so 2016... Our aim is to provide Better Health Data. Rather than collecting data blindly, we believe it is more important to determine which data will be the most appropriate to improve patient care.

Our ambition is to develop clinically validated medical applications to help the patient throughout their journey. 
CE marking and FDA clearance will be seeked to insure our commitment to meet the most stringent regulatory requirements

The future of Medicine

We’re convinced that medicine will evolve from a care approach centered around consultation to a personalized and continuous care, supported by new digital tools. From clinical research to routine care, the possibilities are astounding. 

Regarding public health, mobile applications and connected objects will help create new databases for research within a precise and strictly controlled framework, in line with the health authorities’ guidelines.


Patient is increasingly at the center of health systems. He can rely on new tools to access medical information, patient communities or services to better manage his care pathway. Building on these trends, Ad Scientiam is developing solutions making patients the main actors of their own health

Confidentiality and Ethics

Working on health data is highly sensitive. By meeting strict ethical and confidentiality standards, Ad Scientiam offers reliable solutions to transform patient care

Ad Scientiam in the Press

The patient with MS actor of his own health?

created by Dr Mikaël COHEN - Neurologist Hôpital Pasteur, CHU Nice

We are presenting an application under development, dedicated to patients with Mutiple Sclerosis (MS). This solution aims at facilitating patient...

Ad Scientiam Interview in ""

created by

Find out how Ad Scientiam managed to enter the very exclusive connected health sector

Ad Scientiam invited by ROCHE France at "Hello Tomorrow"

created by hello_tomorrow

Hello Tomorrow: "Where science and technology meet entrepreneurship to build our tomorrow". Ad Scientiam is invited by Roche France